(Date:12/2/2009)..., PHILADELPHIA New study results strengthen the ...ong period of time have an increased risk for deve... other risk factors. , "This provides one more ...e," said senior author Michael J. Thun, M.D., M.S....llance research at the American Cancer Society. "C...
(Date:12/2/2009)..., PHILADELPHIA Mexican-American adolescents expo... likely to pick up the habit themselves, and this ...d with smoking initiation, according to new study ...smoking in the United States and highlights the gl...on Framework Convention on Tobacco Control, which ...
(Date:12/2/2009)... WEST LAFAYETTE, Ind. ╤ A Smoky Mountain for...ate may play a role in how forest understories rec...research. , Despite heavy logging in portions of...of trillium plants on the secondary forest floor w...enkins, a Purdue assistant professor of forestry a...
Breaking Biology News(10 mins):Cigarette smoking increases colorectal cancer risk 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Study finds logging effects vary based on a forest's history, climate 2Service Outsourcing Opportunities in Medical Device Market worth US 2426 77 Billion by 2014 6193 1Service Outsourcing Opportunities in Medical Device Market worth US 2426 77 Billion by 2014 6193 2Service Outsourcing Opportunities in Medical Device Market worth US 2426 77 Billion by 2014 6193 3SciScout LLC Launches SciAnswers com a Science Based Questions and Answers 28Q 26amp 3BA 29 Site with a Social Networking Perspective 14806 1SciScout LLC Launches SciAnswers com a Science Based Questions and Answers 28Q 26amp 3BA 29 Site with a Social Networking Perspective 14806 2SciScout LLC Launches SciAnswers com a Science Based Questions and Answers 28Q 26amp 3BA 29 Site with a Social Networking Perspective 14806 3SciScout LLC Launches SciAnswers com a Science Based Questions and Answers 28Q 26amp 3BA 29 Site with a Social Networking Perspective 14806 4Stemedica President Invited To Lecture At The University Of Oxford 61211 1Stemedica President Invited To Lecture At The University Of Oxford 61211 2Stemedica President Invited To Lecture At The University Of Oxford 61211 3(Date:12/2/2009)...alif., Dec. 2 Peregrine ...ted completion of patient enrollment in a dose con...atients with relapsed glioblastoma multiforme (GBM...a targeted monoclonal antibody linked to a radiois... for GBM. Cotara specifically targets cells at th...
(Date:12/2/2009)...D, The Netherlands, December 2 Pep...gy company focusing on protein mimicking,technolog...announced that it,has appointed Wim E.M. Mol, Ph.D...ol will be responsible for all of Pepscans corpora...gic direction of the company. He brings to,Pepscan...
(Date:12/2/2009)...ORE, Dec. 2 S*BIO Pte Ltd today an...inhibitor, SB1518, at The American Society of Hema...rleans. ,, Data will be presented on the clinic...of SB1518 detailing its safety, tolerability and p...dose levels ranging from 100 to 600 mg. These dose...
(Date:12/2/2009)... Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris ... global biopharmaceutical company focused on endoc...e U.S. Food and Drug Administration (FDA) has gran...Akt pathway inhibitor compound, perifosine (KRX-04...iple myeloma. Keryx Biopharmaceuticals, Inc. ("Ker...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3...ilestone achieved bringing Enerkem one step closer...d biochemicals to commercially use waste, feeds...m Inc., a leading advanced biofuels and biochemica...rst commercial-scale plant located in Westbury, Qu...uction of its clean conditioned synthesis gas. , C...
...ucted by Novartis to evaluate safety and efficacy ...ination with ribavirin in patients with genotypes ... Human Genome Sciences, Inc. (Nasdaq: HGSI ) to...n a Phase 2b trial that will evaluate the safety a...) administered monthly in combination with ribavir...
...R, Jersey, January 12 , - Reflects Strong Int...f,World,s Leading IP Management Specialist and Leg...ld,s top intellectual property,( http://www.cpaglo... provider,of outsourced legal support services, ha...launch of a new brand worldwide. , Founded in ...
Other Biology Technology:Enerkem announces first commercial-scale biofuels and biochemicals plant is entering start-up phase 2Enerkem announces first commercial-scale biofuels and biochemicals plant is entering start-up phase 3Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 2Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 3Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 4Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 5CPA Global Marks 40th Anniversary With Launch of New Brand 2CPA Global Marks 40th Anniversary With Launch of New Brand 3Epi-Grids Colony Grid Templates-24 Squares from EPICENTRE Biotechnologies
Mouse IgG3 EIA Kit from Assay Designs/Stressgen Bioreagents
...ains 200 g of lyophilized peptide derived from the...ds 380-402; GLTPSAWEASSLRSSRHSGLSHF. This peptid...s EP1 receptor polyclonal antibody (Catalog No. 10...ibody to block protein-antibody complex formation ...
Goat Anti-Mouse Ig + IgM Antibody, FITC Conjugated from Cayman Chemical
Biology Products: